Cover Image

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis

AK111 is an innovative IL-17A antibody, presenting high affinity to IL-17A and showing similar pharmacokinetic (PK) characteristics to those of typical immunoglobulin (Ig) G1 antibodies. To optimize the dosage regimen for phase 2/3 clinical trials, PK and pharmacodynamics (PD) of AK111 were first ch...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qian Li (Author), Ju Qiao (Author), Hongzhong Jin (Author), Benchao Chen (Author), Zhimei He (Author), Guoqin Wang (Author), Xiang Ni (Author), Max Wang (Author), Michelle Xia (Author), Baiyong Li (Author), Rui Chen (Author), Pei Hu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
by: Christopher John Wynne, et al.
Published: (2023)

Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
by: Yanyan Zhang, et al.
Published: (2024)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
by: Karine Rodríguez-Fernández, et al.
Published: (2022)

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers
by: Min Wu, et al.
Published: (2022)

Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
by: Luis Puig, et al.
Published: (2021)

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
by: Yuqian Wang, et al.
Published: (2023)

ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer
by: Chun-Lin Lin, et al.
Published: (2020)

Mutation in FAM111B Causes Hereditary Fibrosing Poikiloderma with Tendon Contracture, Myopathy, and Pulmonary Fibrosis
by: Fuying Chen, et al.
Published: (2019)

Sevim Ak`ın Öykülerinin Eğitsel İletileri
by: Serap UZUNER YURT, et al.
Published: (2016)

Alteration of reactive oxygen species master transcription factor Nrf2 in keratinocytes exposed to monoclonal pathogenic antibody AK23 against desmoglein-3 in pemphigus vulgaris
by: Faris Mohsin Ali Alabeedi
Published: (2024)

Impact of NHS 111 Online on the NHS 111 telephone service and urgent care system: a mixed-methods study
by: Janette Turner, et al.
Published: (2021)

Surgery 101 Podcast: Episodes 111-120
by: Jonathan White, et al.
Published: (2013)

A multimethod study of NHS 111 online
by: Turnbull Joanne, et al.
Published: (2023)

Novel glyproline GZK-111 with neuropsychotropic activity
by: K. N. Koliasnikova, et al.
Published: (2022)

Glycemic control in critically 111: A review
by: Preeti Anand, et al.
Published: (2017)

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics
by: Mohamed A. Kamal, et al.
Published: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
by: David Monteith, et al.
Published: (2017)

Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
by: Caleb Jeon, et al.
Published: (2017)

Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis
by: Hongzhong Liu, et al.
Published: (2024)

Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
by: Junzhen Wu, et al.
Published: (2023)

Determinants of depression in 111 italian patients with systemic sclerosis
by: R. Scorza, et al.
Published: (2011)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024)

Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
by: Rocio Lledo‐Garcia, et al.
Published: (2022)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
by: Hongmei Cui, et al.
Published: (2021)

Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
by: Mary Catherine G. Pangilinan, et al.
Published: (2020)

IL-17 Monoclonal Antibody Related HPV Exacerbation: A Case Report
by: Fahrettin Küçükhemek, et al.
Published: (2024)

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
by: Nyholm N, et al.
Published: (2023)

Efficacy and safety of secukinumab for moderate to severe plaque psoriasis in children: A report of 10 cases
by: FU Tao, et al.
Published: (2024)

AK2 Promotes the Migration and Invasion of Lung Adenocarcinoma by Activating TGF-β/Smad Pathway In vitro and In vivo
by: Fangfang Cai, et al.
Published: (2021)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016)

Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy
by: Hua Zhang, et al.
Published: (2022)

Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total
by: John Hood, et al.
Published: (2021)

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
by: A. V. Samtsov, et al.
Published: (2018)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017)

Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects
by: Wei Wei, et al.
Published: (2023)

Detection of mosaic 15q11.1-q11.2 deletion encompassing NBEAP1 and POTEB in a fetus with diffuse lymphangiomatosis
by: Chih-Ping Chen, et al.
Published: (2017)

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
by: Liu L, et al.
Published: (2016)

A Novel lncRNA, AK130181, Contributes to HIV-1 Latency by Regulating Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells
by: Haiyu Li, et al.
Published: (2020)

ASPÉK SOSIOLOGI SASTRA DINA NOVEL SAÉNI KARANGAN HADI AKS
by: Adiwisastra, Prayoga
Published: (2014)

Pharmacodynamic modeling of moderate sedation and rationale for dosing using midazolam, propofol and alfentanil
by: Jing-Yang Liou, et al.
Published: (2023)